Search results
Results From The WOW.Com Content Network
In June 2012, the U.S. Food and Drug Administration (FDA) approved a combination vaccine against two types of meningococcal diseases and Hib disease for infants and children 6 weeks to 18 months old. The vaccine, Menhibrix , was designed to prevent disease caused by Neisseria meningitidis serogroups C and Y, and Haemophilus influenzae type b (Hib).
Meningococcal meningitis is a form of bacterial meningitis. Meningitis is a disease caused by inflammation and irritation of the meninges , the membranes surrounding the brain and spinal cord. In meningococcal meningitis this is caused by the bacteria invading the cerebrospinal fluid and circulating through the central nervous system .
In cases of meningococcal meningitis, preventative treatment in close contacts with antibiotics (e.g. rifampicin, ciprofloxacin or ceftriaxone) can reduce their risk of contracting the condition, but does not protect against future infections. [48] [69] Resistance to rifampicin has been noted to increase after use, which has caused some to ...
There is a paucity of information regarding the optimal treatment regiment for multi-drug resistant tuberculosis meningitis (which is by definition resistant to isoniazid and rifampin), but fluoroquinolones and aminoglycosides can achieve adequate brain and spinal cord penetration and are often used. [4]
Rifampicin can be used as monotherapy for a few days as prophylaxis against meningitis, but resistance develops quickly during long-term treatment of active infections, so the drug is always used against active infections in combination with other antibiotics. [26]
The first-of-its-kind shot addresses the five most common causes of meningococcal disease, Pfizer says. Skip to main content. 24/7 Help. For premium support please call: 800-290-4726 more ways ...
NmVac4-A/C/Y/W-135 is the commercial name for a polysaccharide vaccine that protects against meningococcal meningitis caused by Neisseria meningitidis, specifically the serotypes A, C, Y, and W-135. This vaccine is part of a broader group of meningococcal vaccines .
Meningococcal vaccine refers to any vaccine used to prevent infection by Neisseria meningitidis. [9] Different versions are effective against some or all of the following types of meningococcus: A, B, C, W-135, and Y. [9] [10] The vaccines are between 85 and 100% effective for at least two years. [9]